Evotec AG And Yale University To Collaborate On Cancer Therapy
Published: Dec 17, 2013
HAMBURG, Germany, Dec. 17, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) today announced a research collaboration, TargetDBR (DNA Break Repair), with the laboratories of Prof. Peter Glazer and Prof. Ranjit Bindra at Yale School of Medicine. The objective of this collaboration is to identify novel mechanisms, targets and compounds that have the potential to interfere with DNA repair. DNA repair mechanisms allow cancer cells to cope with extensive genome rearrangements as well as to escape conventional radio- and chemotherapy and thus have potential applications in many cancer indications. This is the first collaboration to be announced as part of Evotec's open innovation alliance with Yale University.
Help employers find you! Check out all the jobs and post your resume.